$249 Million is the total value of Tamarack Advisers, LP's 22 reported holdings in Q1 2019. The portfolio turnover from Q4 2018 to Q1 2019 was 61.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MDRX | Buy | ALLSCRIPTS HEALTHCARE SOLUTIequity | $33,867,000 | +15.2% | 3,550,000 | +16.4% | 13.44% | +12.1% |
| MDT | Buy | MEDTRONIC PLCequity | $31,878,000 | +27.4% | 350,000 | +27.3% | 12.66% | +24.1% |
| SRCL | Buy | STERICYCLE INCequity | $27,754,000 | +78.0% | 510,000 | +20.0% | 11.02% | +73.3% |
| PTLA | Buy | PORTOLA PHARMACEUTICALS INCequity | $25,158,000 | +222.2% | 725,000 | +81.2% | 9.99% | +213.7% |
| LNTH | Sell | LANTHEUS HOLDINGS INCequity | $23,256,000 | +52.4% | 950,000 | -2.6% | 9.23% | +48.4% |
| BIO | Buy | BIO-RAD LABORATORIES-Aequity | $19,869,000 | +42.6% | 65,000 | +8.3% | 7.89% | +38.8% |
| RIGL | Sell | RIGEL PHARMACEUTICALS INCequity | $13,621,000 | +7.7% | 5,300,000 | -3.6% | 5.41% | +4.8% |
| PCRX | New | PACIRA PHARMACEUTICALS INCequity | $12,179,000 | – | 320,000 | +100.0% | 4.84% | – |
| ATRC | Sell | ATRICURE INCequity | $11,386,000 | -38.0% | 425,000 | -29.2% | 4.52% | -39.6% |
| HOLX | Buy | HOLOGIC INCequity | $10,890,000 | +32.5% | 225,000 | +12.5% | 4.32% | +29.0% |
| NVRO | New | NEVRO CORPequity | $10,002,000 | – | 160,000 | +100.0% | 3.97% | – |
| CORV | Buy | CORREVIO PHARMA CORPequity | $7,584,000 | +43.3% | 2,400,000 | +12.9% | 3.01% | +39.5% |
| ALKS | New | ALKERMES PLCequity | $5,109,000 | – | 140,000 | +100.0% | 2.03% | – |
| SCI | Sell | SERVICE CORP INTERNATIONALequity | $4,818,000 | -56.5% | 120,000 | -56.4% | 1.91% | -57.6% |
| OPHT | Buy | OPHTHOTECH CORPequity | $4,230,000 | +252.5% | 3,000,000 | +200.0% | 1.68% | +243.4% |
| OBLN | Sell | OBALON THERAPEUTICS INCequity | $2,944,000 | -32.3% | 2,044,440 | -2.6% | 1.17% | -34.1% |
| TMO | New | THERMO FISHER SCIENTIFIC INCequity | $2,737,000 | – | 10,000 | +100.0% | 1.09% | – |
| STRM | STREAMLINE HEALTH SOLUTIONSequity | $2,048,000 | +29.6% | 1,950,000 | 0.0% | 0.81% | +26.2% | |
| CMD | New | CANTEL MEDICAL CORPequity | $2,007,000 | – | 30,000 | +100.0% | 0.80% | – |
| New | SPY US 04/18/19 P275put | $420,000 | – | 4,000 | +100.0% | 0.17% | – | |
| VSI | Sell | VITAMIN SHOPPE INCequity | $93,000 | -96.7% | 13,158 | -97.8% | 0.04% | -96.8% |
| New | MDCO US 04/18/19 P22put | $34,000 | – | 1,714 | +100.0% | 0.01% | – | |
| Exit | PTLA US 03/15/19 C30call | $0 | – | -3,500 | -100.0% | -0.07% | – | |
| OPTN | Exit | OPTINOSE INCequity | $0 | – | -300,000 | -100.0% | -0.76% | – |
| MCK | Exit | MCKESSON CORPequity | $0 | – | -50,000 | -100.0% | -2.25% | – |
| NXTM | Exit | NXSTAGE MEDICAL INCequity | $0 | – | -625,000 | -100.0% | -7.29% | – |
| Exit | NOVOCURE LTDequity | $0 | – | -670,000 | -100.0% | -9.15% | – | |
| NUVA | Exit | NUVASIVE INCequity | $0 | – | -500,000 | -100.0% | -10.10% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-05-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| VERADIGM ORD | 32 | Q3 2023 | 13.9% |
| STREAMLINE HEALTH SOLUTIONS ORD | 30 | Q3 2023 | 4.0% |
| ATRICURE ORD | 29 | Q3 2023 | 7.6% |
| PACIRA PHARMACEUTICALS INC | 27 | Q1 2023 | 12.1% |
| LANTHEUS HOLDINGS ORD | 25 | Q4 2022 | 9.6% |
| MEDTRONIC PLC | 21 | Q1 2022 | 12.7% |
| RIGEL PHARMACEUTICALS ORD | 21 | Q2 2023 | 8.0% |
| BIO RAD LABORATORIES CL A ORD | 19 | Q2 2023 | 10.0% |
| HOLOGIC INC | 17 | Q1 2022 | 6.5% |
| SPY US 10/21/16 P210 | 17 | Q3 2023 | 41.5% |
View Tamarack Advisers, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| STREAMLINE HEALTH SOLUTIONS INC. | June 22, 2023 | 5,514,515 | 9.4% |
| IVERIC bio, Inc. | February 16, 2021 | 850,000 | 0.1% |
| Correvio Pharma Corp. | February 14, 2020 | 2,500,000 | 4.9% |
| OBALON THERAPEUTICS INC | February 14, 2020 | ? | ? |
| Correvio Pharma Corp. | February 15, 2019 | ? | ? |
| Corium International, Inc. | February 15, 2017 | 737,242 | 3.3% |
| ENDOLOGIX INC /DE/Sold out | February 15, 2017 | 0 | 0.0% |
| Imprivata IncSold out | February 15, 2017 | 0 | 0.0% |
View Tamarack Advisers, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-09 |
| 13F-HR | 2023-11-16 |
| 13F-HR | 2023-08-10 |
| SC 13D/A | 2023-06-22 |
| 13F-HR | 2023-05-11 |
| 13F-HR | 2023-02-13 |
| SC 13D/A | 2022-12-01 |
| 13F-HR | 2022-11-15 |
| 13F-HR | 2022-08-16 |
| 13F-HR | 2022-05-11 |
View Tamarack Advisers, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.